targeted radionuclide therapy

Open Access
MHC-I–Driven Antitumor Immunity Counterbalances Low Absorbed Doses of Radiopharmaceutical Therapy
Julie Constanzo, Aliasghar Parach, Timothee David, Joshua Karam, Frank Bruchertseifer, Alfred Morgenstern, Marta Jarlier, Manuel Bardiès, Emmanuel Deshayes, Amelie Gudin-de-Vallerin, Florence Boissière-Michot, Evelyne Lopez-Crapez and Jean-Pierre Pouget

Journal of Nuclear Medicine May 1, 2025, 66 (5) 785-792; DOI: https://doi.org/10.2967/jnumed.124.268857
Open Access
Preclinical Evaluation of a Radiotheranostic Single-Domain Antibody Against Fibroblast Activation Protein α
Yana Dekempeneer, Sam Massa, Francis Santens, Laurent Navarro, Marion Berdal, Melissa Miranda Lucero, Ana Rita Pombo Antunes, Tony Lahoutte, Jo A. Van Ginderachter, Nick Devoogdt and Matthias D’Huyvetter

Journal of Nuclear Medicine December 1, 2023, 64 (12) 1941-1948; DOI: https://doi.org/10.2967/jnumed.123.266381
You have access
Membrane and Nuclear Absorbed Doses from ¹⁷⁷Lu and ¹⁶¹Tb in Tumor Clusters: Effect of Cellular Heterogeneity and Potential Benefit of Dual Targeting—A Monte Carlo Study
Alexandre Larouze, Mario Alcocer-Ávila, Clément Morgat, Christophe Champion and Elif Hindié

Journal of Nuclear Medicine October 1, 2023, 64 (10) 1619-1624; DOI: https://doi.org/10.2967/jnumed.123.265509
Open Access
Modeling Early Radiation DNA Damage Occurring During ¹⁷⁷Lu-DOTATATE Radionuclide Therapy
Giulia Tamborino, Yann Perrot, Marijke De Saint-Hubert, Lara Struelens, Julie Nonnekens, Marion De Jong, Mark W. Konijnenberg and Carmen Villagrasa

Journal of Nuclear Medicine May 1, 2022, 63 (5) 761-769; DOI: https://doi.org/10.2967/jnumed.121.262610
You have access
Intraarterial Peptide Receptor Radionuclide Therapy Using ⁹⁰Y-DOTATOC for Hepatic Metastases of Neuroendocrine Tumors
Courtney Lawhn-Heath, Nicholas Fidelman, Bryant Chee, Salma Jivan, Evan Armstrong, Li Zhang, Sheila Lindsay, Emily K. Bergsland and Thomas A. Hope

Journal of Nuclear Medicine February 1, 2021, 62 (2) 221-227; DOI: https://doi.org/10.2967/jnumed.119.241273
Open Access
Preclinical Characterization of the Radioimmunoconjugate ¹¹¹In or ⁹⁰Y-FF-21101 Against a P-Cadherin–Expressing Tumor in a Mouse Xenograft Model and a Nonhuman Primate
Yuichi Funase, Eri Nakamura, Masamichi Kajita, Yasutaka Saito, Shinobu Oshikiri, Michi Kitano, Masahiko Tokura, Akihiro Hino and Tomoya Uehara

Journal of Nuclear Medicine February 1, 2021, 62 (2) 232-239; DOI: https://doi.org/10.2967/jnumed.120.245837
Open Access
Combination Strategies to Improve Targeted Radionuclide Therapy
Tiffany G. Chan, Edward O’Neill, Christine Habjan and Bart Cornelissen

Journal of Nuclear Medicine November 1, 2020, 61 (11) 1544-1552; DOI: https://doi.org/10.2967/jnumed.120.248062
Open Access
¹⁷⁷Lu-NM600 Targeted Radionuclide Therapy Extends Survival in Syngeneic Murine Models of Triple-Negative Breast Cancer
Reinier Hernandez, Joseph J. Grudzinski, Eduardo Aluicio-Sarduy, Christopher F. Massey, Anatoly N. Pinchuk, Ariana N. Bitton, Ravi Patel, Ray Zhang, Aakarsha V. Rao, Gopal Iyer, Jonathan W. Engle and Jamey P. Weichert

Journal of Nuclear Medicine August 1, 2020, 61 (8) 1187-1194; DOI: https://doi.org/10.2967/jnumed.119.236265
You have access
Preclinical Characterization of ^86/90Y-NM600 in a Variety of Murine and Human Cancer Tumor Models
Joseph J. Grudzinski, Reinier Hernandez, Ian Marsh, Ravi B. Patel, Eduardo Aluicio-Sarduy, Jon Engle, Zachary Morris, Bryan Bednarz and Jamey Weichert

Journal of Nuclear Medicine November 1, 2019, 60 (11) 1622-1628; DOI: https://doi.org/10.2967/jnumed.118.224808
You have access
New Developments in Peptide Receptor Radionuclide Therapy
Guillaume P. Nicolas, Alfred Morgenstern, Margret Schottelius and Melpomeni Fani

Journal of Nuclear Medicine February 1, 2019, 60 (2) 167-171; DOI: https://doi.org/10.2967/jnumed.118.213496

Main menu

User menu

Search

targeted radionuclide therapy

Pages